Gefitinib adopts orphan kinases in leukemia

Research output: Contribution to journalReview articlepeer-review


Gefitinib, an orally active small-molecule drug that is used for lung cancer therapy based on its EGFR kinase inhibitory properties, is shown to promote differentiation of leukemic cell lines and primary blasts from AML patients in an EGFR-independent fashion.

Original languageEnglish (US)
Pages (from-to)2600-2601
Number of pages2
Issue number8
StatePublished - Oct 2005

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Gefitinib adopts orphan kinases in leukemia'. Together they form a unique fingerprint.

Cite this